CellNetix Names Dr. Danbin Xu as Chief Scientific Officer

CellNetix Pathology & Laboratories is proud to announce that Danbin Xu, M.D., Ph.D. has been promoted to serve as Chief Scientific Officer. In her new role, Dr. Xu will provide strategic leadership, coordination, expertise and management of all scientific and technological innovations and research operations for the laboratory.

Dr. Xu joined CellNetix in 2013 as Technical Director of Molecular Pathology where she has been instrumental in the research and development of its next-generation sequencing (NGS) program, as well as other areas in the molecular department.

“Dr. Xu’s leadership and expertise have been invaluable in the development and implementation of our clinical molecular oncology tests, including NGS-based oncology testing for both solid tumor and hematologic malignancies,” says CEO, Kathleen Fondren. “As CellNetix continues to grow our testing menu for today and the future of pathology, we are very fortunate to have an exceptional talent in Dr. Xu.”

Before joining CellNetix, Dr. Xu was Director of the molecular diagnostics laboratory at Providence Sacred Heart Medical Center in Spokane, WA, where she had designed and implemented their NGS program. She also served as Program Director and Training Director for the hospital’s ABMG-Accredited Clinical Molecular Genetics Fellowship Program.

Dr. Xu has an M.D. from Tianjin Medical University in China and a Ph.D. in Microbiology and Molecular Genetics from Michigan State University. She completed her Clinical Molecular Genetics Fellowship at the University of Washington and is board certified by the American Board of Molecular Genetics and Genomics.